New laser hope for eye fluid disorder
NCT ID NCT06346405
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a low-energy laser treatment for central serous chorioretinopathy, an eye condition where fluid builds up under the retina. The 36 participants have not improved with standard medications. The laser aims to reduce fluid and improve vision by targeting the back of the eye without damaging tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Subthreshold micropulse laser treatment
- What this could lead to
- If successful, this laser treatment could offer a new option for people with central serous chorioretinopathy who haven't responded to standard medications.
- What could go wrong
- This is a small, early-phase study with only 36 participants, so results may not apply to everyone. The laser may not improve vision or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL SEROUS CHORIORETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Policlinico Agostino Gemelli, IRCCS
RECRUITINGRoma, R, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.